XML 64 R49.htm IDEA: XBRL DOCUMENT v3.3.1.900

Collaborative Research, Development and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended			12 Months Ended
	Oct. 31, 2011	Dec. 31, 2008	Sep. 30, 2008	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2012	Dec. 31, 2015	Dec. 31, 2014	Aug. 31, 2014	Sep. 30, 2013	Jun. 30, 2012	May. 31, 2012	Aug. 31, 2010
Deferred Revenue Arrangement [Line Items]
Accrued research and development liability				$ 6,938,000			$ 7,361,000	$ 6,938,000
Additional revenue recognized								1,100,000
Deferred revenue				0			0	0
Maximum
Deferred Revenue Arrangement [Line Items]
Additional revenue recognized							100,000,000
Astra Zeneca
Deferred Revenue Arrangement [Line Items]
Collaboration Revenue	$ 3,000,000			8,000,000	$ 5,400,000	$ 6,000,000
Deferred revenue				$ 12,800,000			$ 2,700,000	$ 12,800,000
Glaxo Smith Kline
Deferred Revenue Arrangement [Line Items]
Collaboration Revenue		$ 10,000,000
National Institutes of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable									$ 200,000
National Institutes of Health | Hepatic Fibrosis and Cirrhosis
Deferred Revenue Arrangement [Line Items]
Grants receivable										$ 200,000
National Institutes of Health | Autoimmune Disease
Deferred Revenue Arrangement [Line Items]
Grants receivable											$ 600,000
National Institutes of Health | Rheumatoid Arthritis
Deferred Revenue Arrangement [Line Items]
Grants receivable												$ 400,000
National Institute of Allergy and Infectious Diseases | Hepatitis B Virus
Deferred Revenue Arrangement [Line Items]
Grants receivable													$ 1,400,000
National Institute of Allergy and Infectious Diseases | Iss Technology
Deferred Revenue Arrangement [Line Items]
Grants receivable			$ 17,000,000
Research collaboration and license agreement period			5 years

X

- Definition

Accrued research and development expenses current.

+ References

No definition available.

+ Details

Name:	dvax_AccruedResearchAndDevelopmentExpensesCurrent
Namespace Prefix:	dvax_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Research collaboration and license agreement period.

+ References

No definition available.

+ Details

Name:	dvax_ResearchCollaborationAndLicenseAgreementPeriod
Namespace Prefix:	dvax_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_GrantsReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_NationalInstitutesOfHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_HepaticFibrosisAndCirrhosisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_AutoimmuneDiseaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_RheumatoidArthritisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_HepatitisBVirusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dvax_IssTechnologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: